培美曲塞联合铂类一线治疗晚期肺腺癌疗效

目的观察培美曲塞联合顺铂或卡铂一线治疗晚期肺腺癌的疗效及毒性反应。方法经病理确诊的晚期肺腺癌患者62例,给予培美曲塞联合顺铂或卡铂方案全身化疗。其中,培美曲塞联合顺铂治疗41例,联合卡铂21例。培美曲塞500mg/m2,顺铂75mg/m2或卡铂血药浓度-时间曲线下面积(AUC)=5。均为第1天静脉滴注,21d为1个周期,连用2-6个周期。按照实体瘤疗效标准(RECIST)进行疗效评定和按照美国癌症研究所(NCI)毒性评价标准(CTC-AE 3.0)评价毒性反应。结果 62例患者中,无完全缓解(CR)病例,部分缓解(PR)27例,稳定(SD)21例,进展(PD)14例,总有效率为43.5%,疾病控制率为77.4%。所有患者无进展生存期(PFS)为5.7个月;Cox回归多因素生存分析显示,年龄、性别、疾病分期及培美曲塞联合不同铂类对PFS无明显影响(P>0.05)。患者毒性反应较轻。结论培美曲塞联合顺铂或卡铂一线治疗晚期肺腺癌疗效较好,安全性高。

Efficacy of pemetrexed plus platinum compunds as first-line chemotheraphy in advanced lung adenocarcinoma

Objective To observe the clinical efficacy and toxicity of pemetrexed plus a platinum agent(cisplatin or carboplatin) in the patients with advanced lung adenocarcinoma(ALAC).Methods A total of 62 ALAC patients confirmed by pathology was treated with pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2(41 cases) or carboplatin(AUC=5,21 cases).Chemotherapy was performed on day 1,21 days/cycle for 2 to 6 cycles.RECIST was used to evaluate the efficacy,and NCI CTC-AE version 3.0 was used to describe adverse events.Ruesults Of 62 patients,27 cases had partial remission,21 had stable disease and 14 had progressed disease,with a response rate of 43.5% and the disease control rate of 77.4%.The median progression-free survival time was 5.7 months,which was not significantly correlated to age,gender,tumor stage and the combination of pemetrexed plus cisplatin or carboplatin(P>0.05).Conclusion Pemetrexed plus platinum compunds is effective and safe in the treatment of patients with ALAC.